CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IPI Legacy Liquidation Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IPI Legacy Liquidation Co
201 ELLIOTT AVE. W, SUITE 260
Phone: (206) 568-1466p:206 568-1466 SEATTLE, WA  98119  United States Ticker: IMPLQIMPLQ

Filed for Bankruptcy on 12/19/2023
Case #23-80016, filed in the U.S. Bankruptcy Court for the Northern District of Texas (Mega Docket DAL)
This entity represents the bankrupt estate of the former businesses (assets) of Impel Pharmaceuticals Inc that were not sold to JN Bidco LLC on 2/12/2024

Business Summary
IPI Legacy Liquidation Co, formerly Impel Pharmaceuticals Inc., is not engaged in any business operations. The Company doesn’t hold any assets.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Co-Founder, Chief Technology and Development Officer JohnHoekman 42 4/1/2021 7/1/2008
Chief Restructuring Officer BrandonSmith 12/18/2023 12/18/2023
Independent Director DavidAllison 41 6/1/2019 6/1/2019
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Impel Neuropharma Australia Pty Ltd
Impel NeuroPharma Australia Pty Ltd
IMPL
IMPLQ

General Information
Number of Employees: 160 (As of 12/31/2022)
Outstanding Shares: 23,900,031 (As of 11/8/2023)
Shareholders: 67
Stock Exchange: OTC
Federal Tax Id: 263058238
Fax Number: (302) 674-5266


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024